Cargando…
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial
Autores principales: | Cryer, Byron, Li, Chunming, Simon, Lee S, Singh, Gurkirpal, Stillman, Martin J, Berger, Manuela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332426/ http://dx.doi.org/10.1186/ar3664 |
Ejemplares similares
-
GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial
por: Cryer, Byron, et al.
Publicado: (2013) -
Management of NSAID-Associated Upper GI Disorders Using AMCP’s Framework for Quality Drug Therapy
por: Cryer, Byron, et al.
Publicado: (2005) -
Mortality associated with gastrointestinal bleeding events: Comparing short-term clinical outcomes of patients hospitalized for upper GI bleeding and acute myocardial infarction in a US managed care setting
por: Wilcox, C Mel, et al.
Publicado: (2009) -
Specialised orthotic care to improve functioning in adults with neuromuscular disorders: protocol of a prospective randomised open-label blinded end-point study
por: van Duijnhoven, Elza, et al.
Publicado: (2020) -
Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial
por: Sakuma, Masashi, et al.
Publicado: (2022)